Navigation Links
Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
Date:9/23/2009

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

"Late stage prostate cancer remains an obvious and large unmet clinical need," said David Hung, M.D., president and chief executive officer of Medivation. "However, many earlier stage prostate cancers are also inadequately treated, as evidenced by their progression, often rapidly, to late stage disease. Our ultimate goal is to develop MDV3100 for the broadest possible spectrum of prostate cancer disease states. The first step is to develop this product candidate for patients with the most advanced disease and in greatest need. However, we believe that patients with earlier-stage disease may also benefit given the attributes of MDV3100, and we look forward to expanding development to include those patients in potential future studies."

The randomized, placebo-controlled, double-blind, multi-national AFFIRM trial is expected to enroll approximately 1,200 patients at sites in the United States, Canada, Europe, South America, Australia and South Africa. The primary endpoint of the trial is overall survival; secondary endpoints include progression-free survival, safety and tolerability. This trial will evaluate MDV3100 at a dose of 160 mg taken orally once daily versus placebo.

Information about patient eligibility and enrollment can be obtained by calling the AFFIRM study hotline toll-free at 1-888-782-3256.

<
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
2. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
3. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
7. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
8. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
11. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... , M.D., Ph.D. to the Company,s Board of Directors, ... fills a vacancy on the Board of seven members. ... and Corporate Governance Committee and a member of the ... a member of Neurotrope,s Scientific Advisory Board, a position ...
(Date:9/18/2014)... , September 18, 2014 After ... chain community, we,re finally here - the new programme for ... January 2015, part of our global Cool Chain series, has ... here ! As the lines between supply ... put together a programme that is broad and yet specific, ...
(Date:9/18/2014)... Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage ... pain, announced today that it has appointed Mr. ... Director of Clinical Development. During his extensive ... led successful global clinical operations teams, in the US ... clinical development of numerous therapeutics and diagnostics across a ...
Breaking Medicine Technology:Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... 2011 Nationally-acclaimed researcher and award-winning author Dr. Cynthia ... National Conference on Cancer Nursing Research that silver treated ... were supposed to prevent. After testing ... with silver coated or silver impregnated fluid pathway components, ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced the ... shares of its common stock, offered at a price to ... Optimer from this offering are expected to be $67.5 million, ... offering expenses payable by Optimer.  The offering is expected to ...
Cached Medicine Technology:Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research 2Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock 2Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock 3
(Date:9/19/2014)... Abilene, Texas (PRWEB) September 19, 2014 Yisrayl ... article this week expounding on the need to protect children. ... took place with Michael Brown and reminds that there are ... and victimized. Yisrayl says violence is spreading faster than cancer ... character training. , “There are close to seven billion Michaels ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 Today, Zane ... information on why to switch employees to individual health ... employees may be more familiar with traditional, group health ... that makes employees happier. , The new article ... with individual health insurance rather than group health insurance, ...
(Date:9/18/2014)... WA (PRWEB) September 18, 2014 Kent, ... Lake Meridian Chiropractic are pleased to announce that Dawn Kelly ... 24-year-old clinic. Dr. Saggau looks forward to Ms. Kelly ... and administrative talents will make her a key contributor. ... combination of educational, professional, and personal experiences that will ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 A jacket ... body. A jacket typically has sleeves, and fastens in ... is generally lighter, tighter-fitting, and less insulating than a ... others serve as protective clothing. Today, Fecbek, a well-known ... arrivals of trendy men’s jackets; all these items are ...
(Date:9/18/2014)... 2014 "Medical staff need better ways ... maintaining the patient's privacy," said one of two inventors ... in order to supply caregivers with the equipment they ... a prototype for The Helper to make it easier ... turn patient onto his or her side. It also ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says the Michael Brown Scenario Will Continue Without Swift Action in New Post 2Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Cool Jackets Are For Sale At Fecbek.com 2
... America, Inc., a leading medical diagnostic instrument manufacturer ... of Jim Cusack as Director of Business Development ... of Marketing & Medical Affairs, Sysmex America. ... the company,s existing business partnerships and in identifying ...
... 10 Surfers, cancer survivors and supporters ... Pacific Ocean with a special purpose: to show their support for ... Survivor Beach, they will place their surfboards in the sand, one-by-one, ... surfboards. The line will start at Scripps Pier and continue ...
... Boston University School of Medicine (BUSM) and collaborators have ... ,EUK-400 series, which could someday be used to prevent ... brains of radiological terrorism victims. The findings, which appear ... Biological Inorganic Chemistry , describe new agents which can ...
... "Help is Here Express" bus tour will be stopping in ... various cities in order to help uninsured and financially-struggling Iowans ... or nearly free. With the state,s unemployment rate now hitting ... Partnership for Prescription Assistance (PPA) is ready to help state ...
... 10 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... settlement of the legal proceedings related to Lexapro(R) (escitalopram ... with Forest Laboratories, Inc. ("Forest") to acquire several products ... litigation settlement resolves litigation involving Caraco, Forest, Forest Holdings, ...
... today that the U.S. Food and Drug Administration (FDA) ... industry,s first programmable bone conduction hearing solution. The Baha ... adults with conductive hearing loss, mixed hearing loss or ... BP100 improves upon previous systems by offering users the ...
Cached Medicine News:Health News:Sysmex America Names Industry Veteran to Business Development Post 2Health News:Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug. 9 2Health News:Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug. 9 3Health News:New oral agents may prevent injury after radiation exposure 2Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 3
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Antigen-Antibody Pens-Using a proprietary and patented technology, ... pens, called Antigen-Antibody pens-TM, that will allow ... membranes in any form or shape or ... helps to see antigen being written on ...
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... 350 Liters of pure water, Complete, Compact ... Purified Water,Millipores compact S.D.S. Storage and Distribution ... 350 liters of purified water produced by ... consistent purity of stored water, provide effective ...
Medicine Products: